{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-008314","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.186830+00:00","generated_at":"2026-05-16T11:03:16.493025+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"low","headline":"Atossa reports preliminary cash balance of ~$40M, limited other details","bullets":["Estimated cash and cash equivalents of ~$40M as of Dec 31, 2025, preliminary and unaudited.","No quarterly earnings, revenue, or operational results were disclosed in this filing.","Updated corporate presentation likely focuses on (Z)-Endoxifen development strategy per forward-looking statements.","Cash estimate subject to finalization of year-end financial closing procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-008314","json":"https://secwatch.observer/filing/0001193125-26-008314.json","markdown":"https://secwatch.observer/filing/0001193125-26-008314.md","text":"https://secwatch.observer/filing/0001193125-26-008314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526008314/0001193125-26-008314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526008314/atos-20260109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:03:16.493025+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}